{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T14:42:16Z","timestamp":1698244936614},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00105-023-05222-6","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:01:57Z","timestamp":1695031317000},"page":"889-898","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronische Prurigo","Chronic prurigo"],"prefix":"10.1007","volume":"74","author":[{"given":"Manuel P.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"5222_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira\u00a0MP et\u00a0al (2018) European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J\u00a0Eur Acad Dermatol Venereol 32:1059\u20131065","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.21698","volume":"187","author":"L Misery","year":"2022","unstructured":"Misery\u00a0L (2022) Chronic prurigo. Br J Dermatol 187:464\u2013471","journal-title":"Br J Dermatol"},{"key":"5222_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin\u00a0M et al (2021) Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A\u00a0population-based claims data analysis. J\u00a0Eur Acad Dermatol Venereol 35:2270\u20132276","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams\u00a0KA et\u00a0al (2021) Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol 14:67\u201377","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5222_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2340\/00015555-2232","volume":"96","author":"S Bobko","year":"2016","unstructured":"Bobko\u00a0S et al (2016) Intraepidermal nerve fibre density is decreased in Lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions. Acta Derm Venereol 96:404\u2013406","journal-title":"Acta Derm Venereol"},{"key":"5222_CR6","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jdv.16309","volume":"34","author":"MP Pereira","year":"2020","unstructured":"Pereira\u00a0MP et al (2020) Chronic nodular prurigo: clinical profile and burden. A\u00a0European cross-sectional study. J\u00a0Eur Acad Dermatol Venereol 34:2373\u20132383","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2340\/00015555-0305","volume":"87","author":"S St\u00e4nder","year":"2007","unstructured":"St\u00e4nder\u00a0S et\u00a0al (2007) Clinical classification of itch: a\u00a0position paper of the International Forum for the Study of Itch. Acta Derm Venereol 87:291\u2013294","journal-title":"Acta Derm Venereol"},{"key":"5222_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jdv.15275","volume":"33","author":"MP Pereira","year":"2019","unstructured":"Pereira\u00a0MP et\u00a0al (2019) Position statement: linear prurigo is a\u00a0subtype of chronic prurigo. J\u00a0Eur Acad Dermatol Venereol 33:263\u2013266","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR9","volume-title":"StatPearls","author":"AS Rice","year":"2023","unstructured":"Rice\u00a0AS et\u00a0al (2023) Kyrle disease. In: StatPearls. FL, Treasure Island"},{"key":"5222_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang\u00a0AH et al (2020) Real-world prevalence of prurigo nodularis and burden of associated diseases. J\u00a0Invest Dermatol 140:480\u2013483.e4","journal-title":"J Invest Dermatol"},{"key":"5222_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaad.2021.09.028","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria\u00a0N et al (2022) Racial disparities in mortality among patients with prurigo nodularis: a\u00a0multi-center cohort study. J\u00a0Am Acad Dermatol 86:487\u2013490","journal-title":"J Am Acad Dermatol"},{"key":"5222_CR12","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","volume":"31","author":"KM Jorgensen","year":"2017","unstructured":"Jorgensen\u00a0KM et\u00a0al (2017) Anxiety, depression and suicide in patients with prurigo nodularis. J\u00a0Eur Acad Dermatol Venereol 31:e106\u2013e107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR13","doi-asserted-by":"publisher","first-page":"adv00424","DOI":"10.2340\/00015555-3778","volume":"101","author":"EC Gwillim","year":"2021","unstructured":"Gwillim\u00a0EC et\u00a0al (2021) Impact of itch on sleep disturbance in patients with prurigo nodularis. Acta Derm Venereol 101:adv424","journal-title":"Acta Derm Venereol"},{"key":"5222_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.15145","volume":"33","author":"E Brenaut","year":"2019","unstructured":"Brenaut\u00a0E et al (2019) The self-assessed psychological comorbidities of prurigo in European patients: a\u00a0multicentre study in 13\u00a0countries. J\u00a0Eur Acad Dermatol Venereol 33:157\u2013162","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jdv.16929","volume":"35","author":"C Zeidler","year":"2021","unstructured":"Zeidler\u00a0C et al (2021) The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: A\u00a0comparative, retrospective, explorative statistical analysis of 4,484 patients in a\u00a0real-world cohort. J\u00a0Eur Acad Dermatol Venereol 35:738\u2013743","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR16","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S et al (2020) IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 5:e42","journal-title":"Itch"},{"key":"5222_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/jdv.15040","volume":"32","author":"J Polking","year":"2018","unstructured":"Polking\u00a0J et\u00a0al (2018) Prurigo Activity Score (PAS): validity and reliability of a\u00a0new instrument to monitor chronic prurigo. J\u00a0Eur Acad Dermatol Venereol 32:1754\u20131760","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5222_CR18","doi-asserted-by":"publisher","first-page":"adv00401","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler\u00a0C et\u00a0al (2021) Investigator\u2019s global assessment of chronic prurigo: a\u00a0new instrument for use in clinical trials. Acta Derm Venereol 101:adv401","journal-title":"Acta Derm Venereol"},{"key":"5222_CR19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch\u00a0G et al (2023) Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase\u00a03\u00a0trials. Nat Med 29:1180\u20131190","journal-title":"Nat Med"},{"key":"5222_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S et al (2020) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N\u00a0Engl J Med 382:706\u2013716","journal-title":"N Engl J Med"},{"key":"5222_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/jdv.17816","volume":"36","author":"E Weisshaar","year":"2022","unstructured":"Weisshaar\u00a0E et al (2022) Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a\u00a0phase\u00a02 randomized controlled trial with an open-label extension phase. J\u00a0Eur Acad Dermatol Venereol 36:453\u2013461","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05222-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05222-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05222-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T14:02:32Z","timestamp":1698156152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05222-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5222"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05222-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"10 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.P.\u00a0Pereira<\/b>: A.\u00a0Finanzielle Interessen: Honorar als Referent\/\u00dcbernahme von Reisekosten: AbbVie, Beiersdorf, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, P.G.\u00a0Unna Academy, Sanofi and Trevi Therapeutics.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Facharzt, Institut f\u00fcr Allergieforschung, Charit\u00e9-Universit\u00e4tsmedizin Berlin | Mitgliedschaften: AGP, EADV, IFSI, SPDV. <b>M.\u00a0Metz<\/b>: A.\u00a0Finanzielle Interessen: Honorare als Referent f\u00fcr: AbbVie, Galderma, gsk, Novartis, Pfizer, Sanofi, Vifor.\u00a0\u2013 Bezahlter Berater f\u00fcr: Amgen, AstraZeneca, argenx, Bayer, Beiersdorf, Celldex, Escient, Galderma, gsk, Incyte, Jasper, Novartis, Pharvaris, Pfizer, Sanofi, Teva, Third Harmonic Bio.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Institut f\u00fcr Allergieforschung, Charit\u00e9-Universit\u00e4tsmedizin Berlin | Mitgliedschaften: ADF, DDG, EADV, ESDR, DGAKI, EAACI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}